US/UK/Canada

Share

Contacts

  • ODI Pharma AB
    Östermalmstorg 1, 11442 Stockholm
    +41765733788
    http://Odipharma.com
    • Pick a time period -
    Tags ( Active)

    ODI Pharma completes final loan repayment and becomes debt-free

    ODI Pharma AB (“ODI” or the “Company”) announces that it has completed the final repayment of its outstanding working capital loan and is now debt-free.Volker Wiederrich, Chairman of the Board, ODI Pharma, comments: "The full repayment of the loan marks the completion of a financing arrangement that supported the Company's commercial expansion. With no remaining interest-bearing liabilities, ODI Pharma enters its next phase with a strengthened balance sheet and increased financial flexibility." The loan, amounting to EUR 350,000, was secured in June 2023 to provide additional

    Publication of interim report Q3 2025/2026

    ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2025 - March 2026. The report is available as an attached document to this press release and on the Company's website (www.odipharma.com). Below is a summary of the report.“ODI Pharma continues to deliver significant and consistent commercial growth, supported by a more stable market environment and improved operating conditions. Over the past three quarters, the Company has achieved record sales levels, and year-to-date sales already exceed any previous full fiscal year in ODI Pharma’s history.

    Publication of half-year report 2025/2026

    ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July 2025 – December 2025. The report is available as an attached document to this press release and on the Company’s website (www.odipharma.com). Below is a summary of the report.Second quarter (2025-10-01 – 2025-12-31) · The Group's net sales amounted to SEK 10,932,119 (0). · The Group's profit after financial items amounted to SEK 1,298,597 (-2,562,520). · Result per share amounted to SEK 0.07 (-0.16).* Six months (2025-07-01 – 2025-12-31) · The Group's net sales amounted to SEK

    ODI Pharma issues a reverse profit warning following improved revenue development

    ODI Pharma AB (“ODI” or the “Company”) today announces a reverse profit warning following a significantly strong revenue development for the period October–December 2025 (Q2).Preliminary and unaudited figures indicate that ODI achieved revenues of approximately SEK 11 million during the second quarter 2025/2026. This corresponds to an increase of approximately 84.3 percent compared to Q1 2025/2026 and a substantial increase compared to the corresponding quarter of the previous fiscal year, when revenues amounted to SEK 0. All figures are preliminary and unaudited. The full results for

    Notice to Annual General Meeting in ODI Pharma AB (publ)

    Today, the 5[th] of December 2025, ODI Pharma AB (publ) held its Annual General Meeting ("AGM"). Below is a summary of the decisions made. All decisions were made with the required majority.Adoption of the income statement and balance sheet The AGM resolved to adopt the profit and loss account and balance sheet presented, and the consolidated income statement and consolidated balance sheet. Allocation of the company's profit or loss The AGM resolved to dispose of the company's results according to the adopted balance sheet, in accordance with the Board's proposal in the annual

    Publication of interim report Q1 2025/2026

    ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2025 - September 2025. The report is available as an attached document to this press release and on the Company's website (www.odipharma.com). Below is a summary of the report.First quarter (2025-07-01 – 2025-09-30) · The Group's net sales amounted to SEK 5,968,143 (143,793). · The Group's profit after financial items amounted to SEK -37,027 (-1,468,183). · Result per share amounted to SEK -0.00 (-0.10).* · The solidity as of 2025-09-30 was 4% (9%).** * The Company’s result per

    ODI Pharma demonstrates clear operational progress and improved commercial outlook

    ODI Pharma AB (“ODI Pharma” or the “Company”) provides an operational update following recent improvements in its commercial performance. Strategic and practical measures implemented in recent quarters have begun to show clear results, supported by a more stable regulatory environment and smoother product flows into the Polish market.ODI Pharma’s commercial activity has strengthened in recent months as earlier operational and strategic measures begin to take effect. The Company now benefits from a more stable supply situation, more predictable import and export processes, and an efficient

    ODI Pharma AB publishes the annual report for the fiscal year 2024/2025

    The Board of Directors and the Chief Executive Officer of ODI Pharma AB (“ODI Pharma”) hereby publishes the annual report for the fiscal year 2024/2025. The annual report, along with the accompanying auditor’s report, is available as an attached file and on the websites of ODI Pharma (www.odipharma.com) and Spotlight Stock Market (www.spotlightstockmarket.com).The auditor has made the following observation: Material uncertainty relating to going concern Without qualifying our opinion, we draw attention to the Directors' report on page 16 and note 18 of the annual accounts and

    Notice to Annual General Meeting in ODI Pharma AB (publ)

    The shareholders of ODI Pharma AB (publ), 559223–1392, are hereby invited to attend the Annual General Meeting on Friday, 5th of December 2025, at 15:00 at the company's premises at Östermalmstorg 1, 114 42 StockholmRight to participate and registrationShareholders who wish to attend the Annual General Meeting shall · be included in the Euroclear Sweden AB share no later than the 27th of November 2025, and · sign up to the company no later than the 1st of December 2025, by e-mail to info@odipharma.com. The notification should state the full name, personal or corporate identity

    ODI Pharma publishes financial calendar for 2025

    ODI Pharma AB (“ODI” or the “Company”) hereby publishes the financial calendar for the 2025/2026 fiscal year.ODI’s updated financial calendar is as follows: · Interim Report Q1 – November 27, 2025 · Annual General Meeting 2025 – December 5, 2025 · Half-year Report – February 26, 2026 · Interim Report Q3 – May 28, 2026 · Year-end Report 2025 – August 27, 2026 For more information on ODI Pharma, please contact: Volker Wiederrich, Chairman, ODI Pharma AB E-mail: info@odipharma.com   ODI Pharma AB ODI Pharma, based on its European network, subsidiaries and

    Publication of year-end report Q4 2024/2025

    ODI Pharma AB (“ODI” or the “Company”) hereby publishes its year-end report for the period July 2024 - June 2025. The report is available as an attached document to this press release and on the Company's website (www.odipharma.com). Below is a summary of the report.Fourth quarter (2025-04-01 – 2025-06-30) · The Group's net sales amounted to SEK 6,461 (7,544,320). · The Group's profit after financial items amounted to SEK -1,660,970 (-1,111,243). • · Result per share amounted to SEK -0.09 (-0.08). Twelve months (2024-07-01 – 2025-06-30) · • The Group's net sales amounted

    Report from the Extraordinary General Meeting

    Today, 26 June 2025, an Extraordinary General Meeting was held in ODI Pharma AB (publ), reg. no. 559223-1392. Below is a summary of the decisions that were made. All decisions were made with the required majority. The notice to the general meeting and complete proposals are available on the Company's website, www.odipharma.com.The Board of Directors' proposals for a resolution on a directed issue of shares (item 7) The meeting approved of the resolution on a directed issue of shares to increase the company's share capital by SEK 70,769.24 through a new issue of 1,769,231 shares. The

    ODI Pharma proposes directed share issue of approximately SEK 2.0 million

    The Board of Directors of ODI Pharma AB (publ) (“ODI Pharma” or the “Company”) has resolved to propose a directed share issue of approximately SEK 2.0 million to strengthen the Company’s financial position, enhance balance sheet flexibility and support the execution of ongoing operational activities. The proposal will be submitted for approval at an Extraordinary General Meeting scheduled to be held on 26 June 2025.Summary The Board of Directors of ODI Pharma has today resolved to propose that an Extraordinary General Meeting (EGM) approve a directed share issue of a total of 2,415,385

    Publication of interim report Q3 2024/2025

    ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2024 - March 2025. The report is available as an attached document to this press release and on the Company's website (www.odipharma.com). Below is a summary of the report.Third quarter (2025-01-01 – 2025-03-31) · The Group's net sales amounted to SEK 2,934,337 (13,856,539). · The Group's profit after financial items amounted to SEK -340,612 (1,389,713). · Result per share amounted to SEK -0.02 (0.09).* Nine months (2024-07-01 – 2025-03-31) · The Group's net sales amounted to

    Publication of half-year report 2024/2025

    ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July 2024 – December 2024. The report is available as an attached document to this press release and on the Company’s website (www.odipharma.com). Below is a summary of the report.Second quarter (2024-10-01 – 2024-12-31) · The Group's net sales amounted to SEK 0 (1,175). · The Group's profit after financial items amounted to SEK -2,562,520 (946,531). · Result per share amounted to SEK -0,16 (0.06).* Six months (2024-07-01 – 2024-12-31) · The Group's net sales amounted to SEK -4,965

    ODI Pharma terminates the agreement with liquidity provider

    ODI Pharma AB ("ODI Pharma") hereby informs the termination of the agreement regarding the liquidity provider with Pareto Securities AB. The last day for the service of liquidity support by Pareto is March 14, 2025.The purpose of the liquidity provider has been to increase the liquidity of stock trading and reduce the volatility of the Company’s stock to facilitate trading. The agreement with Parteo has now been terminated and will expire on March 14, 2025. For more information on ODI Pharma, please contact: Volker Wiederrich, Chairman, ODI Pharma AB E-mail: info@odipharma.com

    Announcement from the Annual General Meeting in ODI Pharma AB (publ)

    Today, the 30[th] of December 2024, ODI Pharma AB (publ) held its Annual General Meeting (“AGM”). A summary of the resolutions follows below. The resolutions were made with the required majority. For more detailed information on the content of the resolutions, please refer to the notice of the Annual General Meeting.Adoption of the income statement and balance sheet The AGM resolved to adopt the profit and loss account and balance sheet presented, and the consolidated income statement and consolidated balance sheet. Allocation of the company’s profit or loss The AGM resolved to

    ODI Pharma AB announces last day of trading in BTA

    ODI Pharma AB’s ("ODI" or the "Company") preferential issue of shares, with a subscription period ending on December 10, 2024, has now been registered at the Swedish Companies Registration Office. The Company hereby announces that the last day of trading in BTA (paid subscribed share) is December 27, 2024, and the stop day is January 2, 2025.In November 2024, ODI carried out a rights issue which provided the Company with approximately SEK 2.2 million before transaction costs. The rights issue has now been registered at the Swedish Companies Registration Office and the last day of trading in

    ODI Pharma AB publishes outcome of rights issue

    The subscription period in ODI Pharma AB’s ("ODI" or the "Company") issue of shares with preferential right (the “Rights Issue”) ended on December 10, 2024. The Rights Issue was subscribed to a total of approximately 54.8 percent, including pre-subscription commitments. ODI will thus be provided proceeds of approximately SEK 2.2 million before deduction of transaction related costs.Subscription, allocation and payment The Rights Issue was subscribed to approximately SEK 2.2 million including pre-subscription commitments of approximately SEK 2.0 million, which corresponds to a

    ODI Pharma achieved market share targets in 2024 and increases its targets for 2025. Positioned for growth as Poland's medical cannabis market expands.

    ODI Pharma AB ("ODI" or the "Company") provides an update on Poland’s expanding medical cannabis market, which remains an important focus of the Company’s strategy. Recent regulatory changes in Poland highlight ODI’s established position in one of Europe’s most promising markets for medical cannabis.With ODI Pharma’s sales during the current calendar year, ODI Pharma reached it’s previously stipulated goal of achieving a substantial market share of more than 10%, resulting in a positive operational result for the shareholders of ODI for the financial year 2023/2024. ODI Pharma has

    Notice of Extraordinary General Meeting in ODI Pharma AB (publ)

    The shareholders of ODI Pharma AB (publ), 559223-1392, are hereby invited to an Extraordinary General Meeting to be held on Tuesday 19 November 2024 at 14.30 at the company's premises at Östermalmstorg 1, 114 42 in Stockholm.Eligibility and registration Shareholders who wish to participate in the General Meeting shall · be entered in the share register maintained by Euroclear Sweden AB on 11 November 2024, and · notify the company no later than on 13 November 2024 by e-mail to info@odipharma.com. The notification shall state full name, personal or corporate identity number,

    Proposal for change in the Board of Directors of ODI Pharma AB

    Malcolm Allan is proposed to be elected as a new member of the Board of Directors of ODI Pharma AB at the Extraordinary General Meeting on November 19, 2024.Malcolm Allan has extensive experience in senior positions within global companies and political campaigns. For the past three years, he has been serving as Vice President at Tilray Brands Inc. Prior to that, he was the Global COO for Havas Media and Managing Director for Prudential in London, UK. He holds a Bachelor of Arts with honors in Political Science and Economics from McGill University.  For more information about the

    ODI Pharma AB decides on a preferential issue of shares and to bring forward publication of the Q1-report

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM SWEDISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. The Board of Directors of ODI Pharma AB ("ODI" or the "Company") has today, on October 30, 2024, resolved to carry out an issue of shares (the "

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe